Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Alterity Therapeutics ( (AU:ATH) ) has provided an announcement.
Alterity Therapeutics Limited has announced the appointment of David Stamler as a director, effective November 21, 2025. This appointment is accompanied by a detailed disclosure of Stamler’s interests in the company’s securities, which include a significant number of fully paid ordinary shares and various options. This move is likely to impact the company’s governance and could influence its strategic direction, reflecting the company’s ongoing commitment to strengthening its leadership team.
More about Alterity Therapeutics
Alterity Therapeutics Limited operates in the biotechnology industry, focusing on developing therapies for neurodegenerative diseases. The company is dedicated to creating innovative treatments to address unmet medical needs in this sector.
Average Trading Volume: 14,994,693
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$97.88M
Find detailed analytics on ATH stock on TipRanks’ Stock Analysis page.